BRPI0705072A2 - grÂnulos mucoadesivos contendo nano e/ou microesferas de quitosana e processo de obtenÇço de grÂnulos mucoadesivos - Google Patents

grÂnulos mucoadesivos contendo nano e/ou microesferas de quitosana e processo de obtenÇço de grÂnulos mucoadesivos

Info

Publication number
BRPI0705072A2
BRPI0705072A2 BRPI0705072-0A BRPI0705072A BRPI0705072A2 BR PI0705072 A2 BRPI0705072 A2 BR PI0705072A2 BR PI0705072 A BRPI0705072 A BR PI0705072A BR PI0705072 A2 BRPI0705072 A2 BR PI0705072A2
Authority
BR
Brazil
Prior art keywords
active compound
granulation
microspheres
chitosan
obtaining
Prior art date
Application number
BRPI0705072-0A
Other languages
English (en)
Inventor
Santana Maria Helena Andrade
Da Silva Classius Ferreira
Fernanda Martins
Original Assignee
Unicamp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unicamp filed Critical Unicamp
Priority to BRPI0705072A priority Critical patent/BRPI0705072B8/pt
Priority to PCT/BR2008/000123 priority patent/WO2008131506A1/en
Publication of BRPI0705072A2 publication Critical patent/BRPI0705072A2/pt
Publication of BRPI0705072B1 publication Critical patent/BRPI0705072B1/pt
Publication of BRPI0705072B8 publication Critical patent/BRPI0705072B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

GRÂNULOS MUCOADESIVOS CONTENDO NANO E/OU MICROESFERAS DE QUITOSANA E PROCESSO DE OBTENÇçO DE GRÂNULOS MUCOADESIVOS. Esta invenção, apresenta um produto, grânulos heterogêneos funcionais contendo um excipiente de granulação e micro e/ou nanopartículas de quitosana encapsulando um composto ativo sensível ao pH, e o seu processo de produção. Estes grânulos incorporam compostos ativos em nano e/ou microparticulas de quitosana, os quais possuem propriedades de mucoadesão e liberação sustentada do composto ativo incorporado. Essas propriedades potencializam maior eficiência de ação in vivo de fármacos ou ativos veiculados quando administrados através de mucosas, redução de efeitos colaterais, preservação da atividade de compostos ativos lábeis e redução da concentração e frequência de doses. O processo de produção pode ser operado em regime semi-contínuo ou descontinuo, em condições estéreis, e permite ser escalonado para aplicação no setor industrial. Inicialmente, o composto ativo é encapsulado em micro ou nanopartículas de quitosana, em dispersão aquosa. Em seguida, as partículas são separadas por centrifugação, e removido o meio aquoso. As partículas úmidas são secas e os excipientes para granulação são adicionados à massa úmida que é submetida ao processo de granulação por extrusão-esferonização.
BRPI0705072A 2007-04-27 2007-04-27 grânulos mucoadesivos contendo nano e/ou microesferas de quitosana e processo de obtenção de grânulos mucoadesivos BRPI0705072B8 (pt)

Priority Applications (2)

Application Number Priority Date Filing Date Title
BRPI0705072A BRPI0705072B8 (pt) 2007-04-27 2007-04-27 grânulos mucoadesivos contendo nano e/ou microesferas de quitosana e processo de obtenção de grânulos mucoadesivos
PCT/BR2008/000123 WO2008131506A1 (en) 2007-04-27 2008-04-28 Mucoadhesive granules containing chitosan nano- and/or microspheres and the process of manufacture

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI0705072A BRPI0705072B8 (pt) 2007-04-27 2007-04-27 grânulos mucoadesivos contendo nano e/ou microesferas de quitosana e processo de obtenção de grânulos mucoadesivos

Publications (3)

Publication Number Publication Date
BRPI0705072A2 true BRPI0705072A2 (pt) 2008-12-09
BRPI0705072B1 BRPI0705072B1 (pt) 2021-03-02
BRPI0705072B8 BRPI0705072B8 (pt) 2021-05-25

Family

ID=39925118

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0705072A BRPI0705072B8 (pt) 2007-04-27 2007-04-27 grânulos mucoadesivos contendo nano e/ou microesferas de quitosana e processo de obtenção de grânulos mucoadesivos

Country Status (2)

Country Link
BR (1) BRPI0705072B8 (pt)
WO (1) WO2008131506A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010041279A2 (en) * 2008-10-08 2010-04-15 V.B. Medicare Pvt. Ltd. Sustained release drug delivery system
WO2011090725A2 (en) * 2009-12-29 2011-07-28 Impax Laboratories, Inc. Gastroretentive solid oral dosage forms with swellable hydrophilic polymer
CN103327970A (zh) * 2010-11-26 2013-09-25 约翰内斯堡威特沃特斯兰德大学 聚合物-脂质纳米粒子的聚合基质作为药物剂型

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1243390B (it) * 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
US20060045865A1 (en) * 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
EP1774971A1 (en) * 2005-10-14 2007-04-18 Advanced in Vitro Cell Technologies, S.L. Chitosan and heparin nanoparticles

Also Published As

Publication number Publication date
BRPI0705072B1 (pt) 2021-03-02
BRPI0705072B8 (pt) 2021-05-25
WO2008131506A1 (en) 2008-11-06

Similar Documents

Publication Publication Date Title
Veerabadran et al. Clay nanotubes for encapsulation and sustained release of drugs
Li et al. Reversal of H1N1 influenza virus-induced apoptosis by silver nanoparticles functionalized with amantadine
ME01458B (me) Kruta dozna forma koja sadrži inhibitor protonske pumpe i njena suspenzija
BR112013000675A2 (pt) nanopartícula, processo para produzir uma nanopartícula compreendendo uma matriz de zeína e um aminoácido básico, processo para produzir uma nanopartícula compreendendo uma matriz de zeína, e um aminoácido básico e um composto biologicamente ativo solúvel em gordura, composição e produto alimentar
BRPI0705072A2 (pt) grÂnulos mucoadesivos contendo nano e/ou microesferas de quitosana e processo de obtenÇço de grÂnulos mucoadesivos
BR112014026957A8 (pt) micropartícula, composição compreendendo a mesma, seu uso e sistema de distribuição nasal relacionados ao tratamento de infecções do trato respiratório superior
JP2012176990A5 (pt)
BR122019027412B8 (pt) composição farmacêutica de liberação sustentada na forma de micropartículas, processo para preparação das ditas micropartículas, e kit de administração
Gadhave et al. Polymers and polymeric materials in COVID-19 pandemic: a review
JP2015515968A5 (pt)
Davidson et al. Bioinspired silica offers a novel, green, and biocompatible alternative to traditional drug delivery systems
BR112013016818A2 (pt) formulação
Rios-Ibarra et al. Nanoparticle‑based antiviral strategies to combat the influenza virus
JP2014530802A5 (pt)
Damasceno Junior et al. Obtaining and applying nanohybrid palygorskite-rifampicin in the pH-responsive release of the tuberculostatic drug
WO2009084041A3 (en) Pharmaceutical compositions of dexibuprofen
WO2010012940A3 (fr) Forme orale microparticulaire utile pour la liberation modifiee de nanoparticules
BR112012030485A2 (pt) composição para prevenção ou tratamento de osteoporose e processo de fabricação para a mesma
Ismael Role of nanotechnology in treating of Toxoplasma gondii
Affrald R et al. Intranasal drug delivery of antiviral agents-a revisit and way forward
MX351668B (es) Zeolitica activada y micronizada, proceso para su activacion y micronizacion y su utilizacion como acarreador en preparaciones farmaceuticas y suplementos alimenticios.
JP2016501225A5 (pt)
Parfenyuk et al. Silicon-based particles as a platform for development of antiviral drugs
de Santana et al. Rifampicin Polymeric Nanoparticles for Tuberculosis: Molecular Dynamics, Physicochemical Characterization and Cytotoxicity
Kumar et al. Microsponges: A Futuristic Approach for Oral Drug Delivery and Current Status.

Legal Events

Date Code Title Description
B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06V Preliminary requirement: patent application procedure suspended [chapter 6.22 patent gazette]
B06A Notification to applicant to reply to the report for non-patentability or inadequacy of the application [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/03/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/04/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF